A comparison of benefits from every-third-day vs. daily low-dose aspirin therapy
4 months ago
- #clinical trial
- #thromboxane
- #aspirin
- Study compares every-third-day vs. daily low-dose aspirin therapy on serum thromboxane concentrations in healthy individuals.
- Aspirin's antithrombotic effect is primarily due to inhibition of platelet cyclooxygenase-1, reducing serum thromboxane A2.
- Randomized, double-blind trial with 109 participants testing different aspirin doses (325 mg, 81 mg, 40 mg) every third day vs. daily 81 mg.
- Serum thromboxane B2 (metabolite of thromboxane A2) measured during and after treatment.
- 325 mg every third day and 81 mg daily showed similar thromboxane inhibition (~85-86%).
- 81 mg every third day achieved 74% inhibition, while 40 mg every third day only 50%.
- Every-third-day regimens (325 mg and 81 mg) may offer equal efficacy with potentially reduced toxicity compared to daily dosing.